Strong Buy
Average AnalystStrong Buy
Top AnalystNeutral
Stock Target AdvisorStrong Buy
Average UserUSD 8.34
0.00 (0.00%)
USD 0.57B
0.75M
USD 25.22(+202.42%)
Based on the Eyepoint Pharmaceuticals Inc stock forecast from 8 analysts, the average analyst target price for Eyepoint Pharmaceuticals Inc is USD 25.22 over the next 12 months. Eyepoint Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Eyepoint Pharmaceuticals Inc is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, Eyepoint Pharmaceuticals Inc’s stock price was USD 8.34. Eyepoint Pharmaceuticals Inc’s stock price has changed by +0.97% over the past week, +5.04% over the past month and -63.36% over the last year.
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company had positive total cash flow in the most recent four quarters.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The stock is trading high compared to its peers median on a price to book value basis.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The company had negative total free cash flow in the most recent four quarters.